Global Erythropoietin - Stimulating Agents market - Growth Trends, and Forecast (2017 - 2022)
Erythropoietin stimulating agents are drugs that are similar to Erythropoietin. This stimulates the growth of red blood cells. ESAs have been approved for the treatment of anaemia due to chronic kidney failure, chemotherapy, HIV, and also for reduced red blood cells during critical surgical procedures. Recombinant Erythropoietin is a biotechnologically derived Erythropoietin and is most widely used. Erythropoietin stimulating agents are utilized to maintain haemoglobin at a low level such that transfusion is minimized but an individual's need is fulfilled.
The increasing incidence and prevalence of anaemia, HIV and cancer and increased application of erythropoietin for various cancer and HIV treatment is propelling the growth of the market. However, stringent regulatory guidelines are turning out to be a restraint for the market.
The erythropoietin stimulating agents market have been segmented based on type and application. The segmentation based on type includes Epoetin - alpha, Epoetin - Beta, Epoetin - Omega, Epoetin - Delta, and Darbepoetin - Alpha. The segmentation based on applications includes cancer chemotherapy, Anemia, Renal disorder, anti-retroviral treatment, neural diseases and others. Darbepoetin is one of the latest group of products that have been marketed but the market for the same is expected to grow rapidly during the forecast period.
The market have been geographically segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The North America have been subdivided into USA, Canada and Mexico. The market in Europe have been subdivided into UK, Germany, France, Italy, Spain, and rest of Europe. The market in Asia-Pacific have been subdivided into Japan, China, India, South Korea, Australia & New Zealand, and rest of Asia-Pacific. The Middle East and Africa have been subdivided into GCC countries, South Africa, and rest of Middle East and Africa. The South America have been segmented into Brazil, Argentina and rest of South America. North America accounted for the largest market value but Asia-Pacific market is expected to grow at a higher CAGR during the forecast period. The emerging economies and new products with better efficacy will be a big opportunity for the market.
The key players in the market are 3S Bio, Amgen, Hoffmann La Roche, Johnson and Johnson, BioSidus, Biocon, Hospira, Intas Pharmaceuticals, Celltrion, and Teva Pharmaceuticals
Market analysis for the Global Erythropoietin stimulating agents market, with region specific assessments and competition analysis.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on regional scale
Extensively researched competitive landscape section with profiles of major companies along with their market shares
Identification and analysis of the macro and micro factors that affect the Erythropoietin stimulating agents market
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped